Skip to main content

Table 2 Genes associated with epithelial ovarian cancer time to recurrence in analysis of tumors from the TCGA and Mayo Clinic (p < 0.01) for both adjusted and unadjusted analyses

From: Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer

Analysis Gene TCGA study Mayo Clinic study
HR 95 % CI P HR 95 % CI P
Adjusted for covariates PTPRCAP 0.71 (0.56,0.89) 0.004 0.14 (0.04,0.40) 3.6E-04
UBASH3A 0.78 (0.65,0.92) 0.005 0.19 (0.06,0.50) 0.001
PPBP 1.18 (1.04,1.33) 0.009 5.79 (1.94,17.21) 0.002
PVRIG 0.73 (0.58,0.91) 0.005 0.28 (0.12,0.62) 0.002
IGKV3-20 0.85 (0.76,0.93) 0.001 0.41 (0.23,0.72) 0.002
FCRL5 0.84 (0.74,0.95) 0.008 0.30 (0.14,0.65) 0.002
ITK 0.83 (0.72,0.95) 0.008 0.30 (0.13,0.66) 0.003
IGHV3OR16-12 0.85 (0.77,0.94) 0.002 0.47 (0.28,0.78) 0.004
VANGL1 0.67 (0.51,0.88) 0.004 0.23 (0.08,0.62) 0.004
SLC16A8 1.23 (1.06,1.43) 0.006 4.55 (1.58,13.01) 0.005
IGKV3-20 0.89 (0.82,0.96) 0.004 0.50 (0.30,0.83) 0.007
ACAP1 0.78 (0.65,0.93) 0.006 0.23 (0.07,0.68) 0.008
Unadjusted for covariates VANGL1 0.73 (0.58,0.92) 0.008 0.26 (0.09,0.69) 0.007
CD38 0.88 (0.80,0.96) 0.007 0.47 (0.28,0.76) 0.003
ELA1 1.42 (1.10,1.82) 0.006 4.93 (1.97,12.32) 0.001
PSME2 0.76 (0.62,0.91) 0.004 0.16 (0.04,0.53) 0.003
UBD 0.92 (0.87,0.97) 0.004 0.59 (0.43,0.81) 0.001
  1. Note, three Agilent probes did not have a current HUGO gene ID and are not presented in the table